Ongoing safety research on Prolia suggests an increased risk of low calcium levels in the blood of patients with advanced kidney disease undergoing dialysis, the FDA said Nov. 22. The twice-a-year drug was approved in 2010 to treat postmenopausal women with osteoporosis at high risk for bone fracture and was later approved to treat men with osteoporosis and other conditions.
As the agency conducts its investigation, the FDA said providers should consider the potential risk for patients on dialysis, frequently monitor blood calcium levels and ensure patients are supplementing adequate amounts of vitamin D and calcium.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
